Conditions: Hypochondroplasia
Keywords: Hypochondroplasia Skeletal dysplasia Growth Growth Hormone Recombinant-human Growth Hormone
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 19
Healthy volunteers: no

Brief summary:
This study is conducted to describe the efficacy and safety of recombinant human growth hormone (r-hGH) treatment Saizen® on children with hypochondroplasia.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: Recombinant human growth hormone (r-hGH)
Intervention descriptions: intervention 1: Subjects will receive a single subcutaneous injection of recombinant human growth hormone (r-hGH) equivalent to a dose of 0.057 milligram per kilogram per day (mg/kg/day). The dose will be subsequently adjusted during the trial and subjects will be treated for at least 3 years or until near final height is reached.

Protocol document: